MiNK Therapeutics, Inc. financial data

Symbol
INKT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
149 Fifth Avenue, Suite 500, New York, New York
State of incorporation
Delaware
Fiscal year end
December 31
Former names
AgenTus Therapeutics, Inc. (to 3/18/2021), AgenTus Therapeutics, Inc. (to 3/18/2021)
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 61.1 % -59.7%
Return On Equity 134 %
Return On Assets -265 % -142%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.7 M shares +2.33%
Common Stock, Shares, Outstanding 34.6 M shares +2.19%
Entity Public Float 20.5 M USD +211%
Common Stock, Value, Issued 347 USD +1.17%
Weighted Average Number of Shares Outstanding, Basic 34.6 M shares +1.99%
Weighted Average Number of Shares Outstanding, Diluted 34.6 M shares +1.99%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.8 M USD -37.2%
General and Administrative Expense 7.05 M USD -4.69%
Operating Income (Loss) -20.9 M USD +29%
Net Income (Loss) Attributable to Parent -20.6 M USD +20.5%
Earnings Per Share, Basic -0.59 USD/shares +23.4%
Earnings Per Share, Diluted -0.59 USD/shares +23.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.82 M USD -60.9%
Other Assets, Current 122 K USD -61.8%
Assets, Current 6 M USD -61.4%
Property, Plant and Equipment, Net 895 K USD -16.1%
Assets 6.89 M USD -58.4%
Accounts Payable, Current 3.49 M USD -41.9%
Accrued Liabilities, Current 5.28 M USD +91.9%
Liabilities, Current 11.1 M USD -1.26%
Other Liabilities, Noncurrent 31.6 K USD -66.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -386 K USD -3.2%
Retained Earnings (Accumulated Deficit) -137 M USD -17.7%
Stockholders' Equity Attributable to Parent -20.3 M USD -354%
Liabilities and Equity 6.89 M USD -58.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.54 M USD +41.8%
Net Cash Provided by (Used in) Financing Activities 5.01 M USD
Net Cash Provided by (Used in) Investing Activities -13.5 K USD
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 34.7 M shares +1.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.45 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.82 M USD -60.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5.12 K USD -48.6%
Deferred Tax Assets, Valuation Allowance 29.7 M USD +31%
Deferred Tax Assets, Gross 29.7 M USD +31%
Depreciation 53.8 K USD +17.8%
Payments to Acquire Property, Plant, and Equipment 13.5 K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -20.6 M USD +21.3%
Property, Plant and Equipment, Gross 1.45 M USD +7.33%
Preferred Stock, Shares Authorized 5 M shares
Share-based Payment Arrangement, Expense 3.63 M USD +14.9%